We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ablynx NV ADS (delisted) | NASDAQ:ABLX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 52.87 | 24.00 | 68.00 | 0 | 01:00:00 |
REGULATED INFORMATION
GHENT, Belgium, 18 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from FMR LLC on 16 and 17 January 2018.
FMR LLC (taking into account the holdings of its subsidiary undertakings) now holds a total of 7,230,164 voting securities of Ablynx, representing 9.68% of the current 74,720,644 outstanding voting rights of Ablynx (versus 9.50% notified previously on 25 August 2017).
FMR LLC has notified Ablynx that FMR Co., Inc., a subsidiary of Fidelity Management & Research Company, which itself is a subsidiary of FMR LLC (the ultimate parent company) has downward crossed the 5% threshold of voting rights of Ablynx since 15 January 2018 and upward crossed the 3% threshold of voting rights held through financial instruments since 16 January 2018.
The notification contains the following information:
Name of select subsidiaries of FMR LLC | % of voting rights | % of voting rights held through financial instruments* | Total of both |
FMR LLC Fidelity Management & Research Company FMR Co., Inc. | 4.41% | 3.21% | 7.62% |
FMR LLC FIAM Holdings Corp. Fidelity Institutional Asset Management Trust Company | 1.05% | 1.05% | |
FMR LLC FIAM Holdings Corp. FIAM LLC | 1.02% | 1.02% | |
TOTAL | 6.47% | 3.21% | 9.68% |
* Type of financial instrument: "Right of Recall
More information is available in the transparency notification. Full versions of both transparency notifications are available on Ablynx website, under the section Investors.
The articles of the association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
1 Year Ablynx NV Chart |
1 Month Ablynx NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions